Risperidone is an antipsychotic medication developed in the 1980s-1990s and approved by the FDA in 1994. It is on the WHO's list of essential medicines. Risperidone is effective at decreasing hallucinations and delusions in psychotic patients, allowing them to function better. It is available in tablet, liquid, and injectable forms. Risperidone is metabolized in the liver and has an oral bioavailability of 70%. Common side effects include extrapyramidal symptoms, weight gain, and hyperprolactinemia. It is indicated for schizophrenia, bipolar mania, autism-related irritability, and other off-label uses, though has black box
antipsychotics history, managment of psychosis,side effect of antipsychotics, mechanism of antipsychotics, atypical antipsychotics,2nd generation antipsychotics.
antipsychotics history, managment of psychosis,side effect of antipsychotics, mechanism of antipsychotics, atypical antipsychotics,2nd generation antipsychotics.
Background: The main aim of present research investigation is to formulate the Risperidone Fast Dissolving tablets. Risperidone, an atypical antipsychotic, belongs to BCS Class-II and used for treating schizophrenia, bipolar mania and autism by blocking D2 and 5-HT2A receptors. Methods: The Fast Dissolving tablets of Risperidone were prepared employing different concentrations of Crospovidone and Croscarmellose sodium in different combinations as a Superdisintegrants by Direct Compression technique using 32 factorial design. The concentration of Crospovidone and Croscarmellose sodium was selected as independent variables, X1 and X2 respectively whereas, wetting time, Disintegration time, t50% ,t90%were selected as dependent variables. Results and Discussion:
Totally nine formulations were designed, preapred and are evaluated for hardness, friability, thickness, Assay, Wetting time, Disintegration time, In-vitro drug release. From the Results concluded that all the formulation were found to be with in the Pharmacopoeial limits and the In-vitro dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for Wetting time, Disintegration time, t50%, t90%. Validity of developed polynomial equations were verified by designing 2 check point formulations (C1, C2). According to SUPAC guidelines the formulation (F5) containing combination of 10% Crospovidone and 10% Croscarmellose, is the most similar formulation (similarity factor f2= 93.556, dissimilarity factor f1= 0.976& No significant difference, t= 0.022) to marketed product (RISPERDAL-4). Conclusion: The selected formulation (F5) follows First order, Higuchi’s kinetics, mechanism of drug release was found to be Fickian Diffusion (n= 0.383).
Risperidone Tablets USP Taj Pharma SmPCTajPharmaQC
Risperidone Tablets USP 0.25mg/0.5mg/1mg/2mg/3mg /4mg Taj Pharma: Uses, Side Effects, Interactions, Pictures, Warnings, Risperidone Dosage & Rx Info | Risperidone Uses, Side Effects Risperidone: Indications, Side Effects, Warnings, Risperidone-Drug Information –Taj Pharma, Risperidone dose Taj pharmaceuticals Risperidone interactions, Taj Pharmaceutical Risperidone contraindications, Risperidone price, Risperidone Taj Pharma Risperidone SmPC-Taj Pharma Stay connected to all updated on Risperidone Taj Pharmaceuticals Mumbai. Patient Information Leaflets, SMPC.
Risperidone Dispersible Tablets Taj Pharma SmPCTajPharmaQC
Risperidone Dispersible Tablets 1mg, 2mg Taj Pharma: Uses, Side Effects, Interactions, Pictures, Warnings, Risperidone Dosage & Rx Info | Risperidone Uses, Side Effects Risperidone: Indications, Side Effects, Warnings, Risperidone-Drug Information –Taj Pharma, Risperidone dose Taj pharmaceuticals Risperidone interactions, Taj Pharmaceutical Risperidone contraindications, Risperidone price, Risperidone Taj Pharma Risperidone SmPC-Taj Pharma Stay connected to all updated on Risperidone Taj Pharmaceuticals Mumbai. Patient Information Leaflets, SMPC.
Risperidone is used to treat psychotic disordersin Children. It acts in brain by affecting levels of dopamine and serotonin which calm the child with severe behavior problems.
For more information visit at
https://bit.ly/2M3svtf.
Share/comment if you know anything about Risperidone.
Second generation atypical anti-psychotic used for mental disorders more extensively for bipolar disorder. have very low side effects than other SGA Medications
We all have good and bad thoughts from time to time and situation to situation. We are bombarded daily with spiraling thoughts(both negative and positive) creating all-consuming feel , making us difficult to manage with associated suffering. Good thoughts are like our Mob Signal (Positive thought) amidst noise(negative thought) in the atmosphere. Negative thoughts like noise outweigh positive thoughts. These thoughts often create unwanted confusion, trouble, stress and frustration in our mind as well as chaos in our physical world. Negative thoughts are also known as “distorted thinking”.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxEduSkills OECD
Andreas Schleicher presents at the OECD webinar ‘Digital devices in schools: detrimental distraction or secret to success?’ on 27 May 2024. The presentation was based on findings from PISA 2022 results and the webinar helped launch the PISA in Focus ‘Managing screen time: How to protect and equip students against distraction’ https://www.oecd-ilibrary.org/education/managing-screen-time_7c225af4-en and the OECD Education Policy Perspective ‘Students, digital devices and success’ can be found here - https://oe.cd/il/5yV
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
3. HISTORY
• Developed by Janssen Clag, subsidy of
Johnson and Johnson 1988-1992
• First approved by FDA in 1994
• Present in WHO list of most important
medications needed in basic health system
5. Antipsychotic drugs are not curative and do
not eliminate the fundamental thinking
disorder, but they often:
1.Decrease the intensity of hallucinations
and delusions.
2.Permit the psychotic patient to function in
a supportive environment.
6. Chemistry and Preparations
• It is Benzisoxizole derivative.
• C23-H27-FN4-O2.
• Trade names :- Risnia, Risdone, Sizodon.
Formulation Strength
Tablet (Including mouth
dissolving)
0.25/0.5/1/2/3/4
Solution 1mg/mL
Injection (Powder for
suspension, ER)
12.5/25/37.5/50
7. PHARMACOKINETICS
Absorption
o PO
• Absolute oral bioavailability is 70%.
• Tmax is 1 hr for Risperidone (parent compound), 3 h (9-
hydroxyrisperidone extensive metabolizers), or 17 h (9-
hydroxyrisperidone poor metabolizers).
• Steady state is approximately 1 day(extensive metabolizers) or
approximately 5 days (poor metabolizers).
• Food - DOES NOT affect absorption.
o IM
• Release of the drug-3rd wk after injection.
Maintained from 4-6 wk.
Subsides by 7th wk.
• Steady state is reached after 4 injections.
8. Distribution
• Rapidly distributed.
• Vd :– 1-2 L/kg.
• Protein binding is approximately 90% (parent compound)
and approximately 77% (9-hydrox yrisperidone).
Metabolism
• Extensively metabolized in liver - CYP2D6 to major active
metabolite 9-hydroxyrisperidone.
• 9-hydroxyrisperidone has similar activity to risperidone.
9. Elimination
• Eliminated in urine (70%) and feces (14%).
o PO
• The half-life is 20 h (overall mean half-life) for
combined risperidone and 9-hydroxyrisperidone.
o IM
• The half-life of risperidone plus 9-
hydroxyrisperidone is 3 to 6 days.
10. MECHANISM OF ACTION
Receptor (NT) Action
D1,D2,D3, D4, D5
(Dopamine)
Blocks mesolimbic pathway, prefrontal cortex, limbic pathway,
tubero-infudibular pathway
5HT2A, 5HT2C
(Serotonin)
2A – ↓ EPS, improvement of –ve symptoms as compared to
typical
2C – Weight gain
α1 High affinity. Orthostatic hypotension, sedation.
α2 Greater +ve, -ve, affective, cognitive symptom control.
H1 Sedation, ↓ in vigilance, drowsiness & weight gain.
•It blocks 65% of D2 receptors (lowest threshold for
antipsychotic efficacy)
•At 6mg/day - 80% of D2 receptors are blocked and EPS
can occur.
11.
12. INDICATIONS AND DOSAGES
ACUTE PSYCHOSIS AND SCHIZOPHRENIA
o ADULTS
• INITIAL DOSE SHOULD NOT BE GREATER THAN 2
MG/DAY,
• DOSE INCREASE OF 1-2 MG/DAY ACCEPTABLE BUT
SHOULD BE SPACED 24 HRS APART
• TARGET DOSE IS 2-8 MG/DAY IN OD/DIVIDED
DOSAGE
13. INDICATIONS AND DOSAGES
o ADOLESCENTS (13 TO 17 Y OF AGE )
• PO INITIATE TREATMENT WITH 0.5 MG ONCE DAILY
AS A SINGLE DOSE IN THE MORNING OR EVENING. IF
INDICATED, DOSAGE ADJUSTMENTS SHOULD BE AT
INTERVALS OF NO LESS THAN 24 H, IN INCREMENTS
OF 0.5 TO 1 MG/DAY, AS TOLERATED, TO A
RECOMMENDED DOSAGE OF 3 MG/DAY (DOSE
RANGE, 1 TO 6 MG/DAY).
• PATIENTS EXPERIENCING PERSISTENT SOMNOLENCE
MAY BENEFIT FROM ADMINISTERING HALF THE DOSE
TWICE DAILY.
14. INDICATIONS AND DOSAGES
BIPOLAR MANIA
o ADULTS
• 2 TO 3 MG/DAY ONCE DAILY INITIALLY. ADJUST
DOSE AT INTERVALS OF NO LESS THAN 24 H, IN
INCREMENTS/DECREMENTS OF 1 MG/DAY (USUAL
DOSAGE, 1 TO 6 MG/DAY). NO DATA TO SUPPORT
SHORT-TERM TREATMENT BEYOND 3 W K.
15. INDICATIONS AND DOSAGES
o ADOLESCENTS (13 TO 17 Y OF AGE )
• START WITH 0.5 MG ONCE DAILY. IF INDICATED,
DOSAGE ADJUSTMENTS SHOULD OCCUR AT
INTERVALS OF NO LESS THAN 24 H AND IN
INCREMENTS OF 0.5 OR 1 MG/DAY, AS
TOLERATED, TO A RECOMMENDED DOSAGE OF
2.5 MG/DAY (DOSE RANGE, 0.5 TO 6 MG/DAY).
16. INDICATIONS AND DOSAGES
IRRITABILITY ASSOCIATED WITH
AUTISTIC DISORDER
• CAN BE ADMINISTERED ONCE DAILY OR HALF THE TOTAL
DAILY DOSE TWICE DAILY. USE CAUTION WITH DOSAGE
FOR CHILDREN WEIGHING LESS THAN 15 KG. FOR
PATIENTS LESS THAN 20 KG, THE INITIAL DOSAGE IS 0.25
MG/DAY. AFTER A MINIMUM OF 4 DAYS, THE DOSAGE
MAY BE INCREASED TO 0.5 MG/DAY. MAINTAIN THIS DOSE
FOR A MINIMUM OF 14 DAYS. I F SUFFICIENT CLINICAL
RESPONSE IS NOT OBTAINED, THE DOSAGE MAY BE
INCREASED IN INCREMENTS OF 0.25MG/DAY AT
INTERVALS OF NO LESS THAN 14 DAYS.
17. • FOR PATIENTS 20 KG OR MORE, THE INITIAL DOSAGE
IS 0.5 MG/DAY. AFTER A MINIMUM OF 4 DAYS, THE
DOSAGE MAY BE INCREASED TO 1 MG/DAY.
MAINTAIN THIS DOSE FOR A MINIMUM OF 14 DAYS.
I F SUFFICIENT CLINICAL RESPONSE IS NOT
OBTAINED, THE DOSAGE MAY BE INCREASED IN
INCREMENTS OF 0.5 MG/DAY AT INTERVALS OF NO
LESS THAN 14 DAYS.
18. INDICATIONS AND DOSAGES
OTHER OFF LABEL USES
– TOURETTE SYNDROME
– PTSD
– PSYCHOSIS RELATED TO ALZHEIMERS
– BEHAVIOUR DISTURBANCES RELATED TO MENTAL
RETARDATION
– TREATMENT RESISTANT OCD
– BIPOLAR DEPRESSION
20. Haematological :- Anemia, epistaxis (rare)
Genito-Urinary :- Ejaculatory disorder,
priapism, sexual dysfunction (men), non
purpural lactation and menstrual irregularities
(women) [d/t hyperprolactinemia]
Dermatological :- Rash, giant urticaria &
angioedema
21. Black Box warning
• Increased Mortality in Elderly Patients with Dementia-Related
Psychosis :- Elderly patients with dementia-related psychosis
treated with antipsychotic drugs are at an increased risk of
death.
• Cerebrovascular Adverse Reactions, Including Stroke, in
Elderly Patients with Dementia-Related Psychosis :-
Cerebrovascular adverse reactions (e.g., stroke, transient
ischemic attack), including fatalities were reported in patients
(mean age 85 years; range 73-97) in trials of risperidone in
elderly patients with dementia-related psychosis. Risperidone
is not approved for the treatment of patients with dementia-
related psychosis.
22. • Neuroleptic Malignant Syndrome
• Clinical manifestations
1. Hyperpyrexia, muscle
rigidity, altered mental
status, and autonomic
instability (irregular pulse or blood
pressure, tachycardia, diaphoresis, and
cardiac dysrhythmia).
2. Additional signs may
include elevated creatine
phosphokinase (CPK),
myoglobinuria,
rhabdomyolysis, and acute
renal failure.
• Management
1. Immediate discontinuation
of antipsychotic drugs
2. Intensive symptomatic
treatment and medical
monitoring
3. Treatment of any
concomitant serious
medical problems for which
specific treatments are
available.
23. Tardive Dyskinesia
• A syndrome of potentially irreversible,
involuntary, hyperkinetic movements.It causes
facial movements like constant chewing,tongue
protrusion&facial grimacing.
• Caused D/t chronic blokage of nigrostriatal
pathway.
• T/t- non-specific pharmachotherapy, but
discontinuation of drug may help
24. • Hypercholesterolemia,Hyperglycemia &
Diabeties Mellitus :- less risk than other anti
psychotics.
• Orthostatic Hypotension & Syncope :- due to α-
receptor antagonist properties
• Hyperprolactinemia :-
– ↑ prolactin levels [mean of 15.4 ng/dL].
– ↓ reproductive functioning - galactorrhea, amenorrhea,
anorgasmia. If left untreated, leads to decreased bone
mineral density in both sexes, with hypogonadism.
– F/H/O Breast cancer s/b enquired before T/t.
25. Special population
• Pregnancy :- Category C drug.
• Lactation :- Excreted in breast milk.
Milk : plasma conc. < 0.5
• Geriatric :- Use cautiously as prone for
orthostatic hypotension. Concomitant
administration with Furosemide increases risk
of mortality in elderly patients.
27. DRUG INTERACTIONS
• Inhibition of CYP2D6 by drugs such as
paroxetine & Fluoxetine blocks formation of
active metabolite.
• Combined use of risperidone with SSRI can
result in significant hyperprolactnemia.